May
3
Thu
2018
Pre registration is required
Contact the organizer to register
- The Need for Follow-through with REAL MS
- #AAN2018 – Mavenclad Potently Suppresses the Number of Memory B-cells in RRMS, Study Shows
- #AAN2018 – MS Progresses Quickly in Blacks and May Warrant More Aggressive Treatment
- Marking the 1-year Anniversary of ‘MS In Motion’
- #AAN2018 – Review of Phase 3 Trial Data Supports Gilenya as Treatment for Pediatric MS
- #AAN2018 — ALKS 8700 Shows Promise as RRMS Therapy, Phase 3 Trial Interim Results Suggest
- This Was Me Before Multiple Sclerosis: A Letter to MS
- Research Reveals Another Possible Epstein-Barr Virus Link to MS